This study evaluates the diagnostic performance and safety of F-18-PSMA-1007 and F-18-Fluorocholine PET/CT imaging in patients with suspected recurrence of prostate cancer after previous definitive treatment.

Inclusion Criteria:

• male with original diagnosis of prostate carcinoma with prior definitive therapy
• suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2 ng/mL after prostatectomy)
• life expectancy of 6 months or more as judged by the investigator
• willing and able to undergo all study procedures
• informed consent in writing (dated and signed)

Exclusion Criteria:

• age: less than18 years
• contraindications for F-18-Fluorocholine
• contraindications for any of the ingredients of F-18-PSMA-1007
• close affiliation with the investigational site; e.g. first-degree relative of the investigator
• at the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial
• having been previously enrolled in this clinical trial
• mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial
• being clinically unstable or requiring emergency treatment
• being considered a vulnerable person